By Appbay Technologies
One revenue line is declining. The question is whether anyone can see, in real time, whether the pipeline is actually closing that gap.
A global pharma company has named a significant decline in its COVID-19 business, alongside an explicit strategic mandate: innovate fast enough to offset it. That’s a genuinely trackable race – a specific number falling, and a pipeline of new launches meant to rise against it.
A flag up front: Roche is a global pharmaceutical company, not a bank or GCC-based entity, and Appbay has no genuine fit here. This is industry commentary, not a disguised pitch.
The Priority: Innovating Fast Enough to Outrun a Named Decline
Bringing new products to market fast enough to replace a shrinking revenue line is a clear and urgent strategic priority. Roche has explicitly named the COVID business decline as significant, meaning the pipeline gap it creates is quantifiable and board-tracked, not vague.
Pipeline replacement isn’t just “innovate more.” It requires the R&D-to-launch process itself to move faster than the COVID revenue decline is compounding – a race against a specific, named, shrinking number.
The Hidden Problem: Two Lines, No Shared Scoreboard
Here’s where the operational gap actually shows up, inside a pharma company replacing a declining legacy revenue line:
COVID revenue, declining on record – a specific, quantifiable, board-tracked decline New launches, tracked separately – pipeline progress lives therapeutic-area by therapeutic-area, not consolidated against the decline it’s meant to offset Unmet needs, genuinely different by region – global pipeline targeting has to account for diverse patient populations and healthcare systems simultaneously No single view of the gap closing – nobody has an easy answer to “are we winning this race” until well after the fact
Why does this exist? Pipeline-to-revenue tracking is likely siloed by therapeutic area, without a consolidated view of whether new launches are actually offsetting the decline at the pace needed. The declining legacy revenue is tracked separately in finance, while pipeline progress lives with R&D – two views of the same race, never brought together.
Why This Matters Now
“Innovate to offset the decline” is the mandate. Proving the gap is closing is the harder part.
The question that follows isn’t rhetorical:
“The mandate is offsetting the decline. Can anyone show, in real time, whether the pipeline is actually closing that gap?”
For the Head of R&D or CFO, this plays out as a live visibility problem, tracked against a question most reporting structures aren’t built to answer:
Revenue replaced, by launch – which specific launches are actually contributing to closing the gap? Time from pipeline to offset – how long does it take a new product to meaningfully offset declining legacy revenue? One view, every therapeutic area – can the full pipeline be seen against the decline at once, not area by area?
Innovating to offset a decline isn’t the problem. Seeing the race in real time is.
No Credible Existing Fit – An Honest Note
We want to be direct here: Appbay has no credible existing solution for this. Roche is a global pharmaceutical company, far outside Appbay’s GCC banking focus, in scale and domain both. Our actual products are built for banking compliance and workflow automation – not pharmaceutical pipeline tracking or R&D portfolio management.
What we can honestly say: the underlying need – one consolidated view tracking a declining number against a rising one, across multiple business units – is a familiar shape from other industries. But presenting Appbay as positioned to build that here would be inaccurate, and we’re not going to do that.
Why We’re Saying This Plainly
This is genuinely industry commentary, offered because the pattern is interesting and worth naming – not a lead-in to a pitch we can’t credibly make. Roche’s own named challenge is specific and real, and the visibility gap it creates is a pattern worth discussing on its own terms, without pretending Appbay is the team to close it.
This Pattern Isn’t Unique to One Company
Any organization racing a new pipeline against a named, declining legacy revenue line will face the same visibility gap: no single scoreboard showing whether the race is actually being won.
Let’s Compare Notes
Curious how other global pharma companies are tracking pipeline replacement against a declining legacy revenue line. We’re not the right team to build this, but we’re glad to compare notes.
Send us a message – this one’s genuinely about comparing notes, not a pitch.
